Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the New England Journal of Medicine and presented during a Hot Line session at the annual European Society of Cardiology (ESC) Congress in Barcelona.

Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial, presented the MADIT-CRT data. The primary endpoint showed that Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) were associated with a 34 percent relative reduction in the risk of all-cause mortality or first heart failure event in asymptomatic and mild (NYHA Class I and II1) heart failure patients, when compared to standard implantable cardioverter defibrillators (ICDs) (p=0.001).